My Son Called Me His “Scientific Advisor” at the Licensing Meeting. I’m the Sole PI on the NIH Grant. I Hold the Patents. The NIH Compliance Observer Was in the Room.

The licensing suite at Nexagen Biotech was a monument to clinical, corporate efficiency. It was located on the top floor of their Durham headquarters, surrounded by floor-to-ceiling glass that overlooked the vast, sprawling campus of the Research Triangle Park. The morning light hit the steel fixtures and the polished white table, creating a sterile, almost surgical environment.

I was sitting near the back of the room, my leather tote bag placed carefully under my chair. My son, Marcus, was standing at the front of the room, adjusting his laptop and preparing his presentation. Marcus was thirty-four years old, the Vice President of Strategy for NovaMed Analytics, and he was currently attempting to license a massive pharmacological database to Nexagen for four point two million dollars.

He had invited me to the meeting, introducing me to the executives as his ‘scientific advisor’. “My mother,” Marcus had said, gesturing toward me with a smooth, practiced smile when we entered the room. “She understands the science.” He meant it as a compliment, a way of grounding his slick corporate pitch with a touch of maternal, academic credibility. He did not realize the profound irony of the statement. I didn’t just understand the science. I was the science.

Rachel Kim, the Vice President of Licensing for Nexagen, sat directly across from Marcus, her pen poised over a pristine legal pad. Next to her sat Dr. Yemi Adegoke. Dr. Adegoke was not a Nexagen employee. He was a program officer from the National Institutes of Health Office of Extramural Research. He was present in the room strictly as a federal compliance observer, a necessary legal requirement whenever a commercial entity attempts to license intellectual property that was developed using federal grant funding. He had his laptop open, quietly typing, his face completely neutral.

Marcus clicked his presentation remote, bringing up the third slide of his pitch deck. It was the provenance slide, the slide designed to establish the chain of title for the intellectual property.

“NovaMed Analytics developed the POLI-Drug Interaction Database in partnership with academic research teams,” Marcus said, his voice confident and perfectly modulated.

I looked at the slide projected on the massive screen. There, in perfectly crisp corporate font, was my name. Under the heading: ‘Principal Academic Contributor: Dr. P. Obeng.’ I looked at the slide. I looked at the word ‘contributor’. I reached under my chair and touched the heavy leather of my bag. Inside that bag was a framed plaque. It was wrapped in protective bubble wrap, but I knew exactly what the inscription said. I had brought it to give back to him after the deal closed. I was not going to give it to him now.

Dr. Adegoke stopped typing. He looked at the slide projected on the wall. He typed a string of characters into his laptop. He looked at the slide again, and then he looked directly at me.

In nineteen ninety-one, I submitted my first major grant application to the National Institutes of Health. I was working out of a borrowed office in the basement of a pharmacology building in Chapel Hill, using a desktop computer that crashed if I opened more than two spreadsheets at once. I wrote the grant proposal over three grueling weeks of evenings, operating on caffeine and sheer, stubborn determination. When the first cycle was funded, the anonymous peer reviewer had written a single, defining comment at the bottom of the evaluation sheet: “This is the most rigorous drug interaction methodology we have reviewed.” I had kept that comment. It is still in a folder in my home office.

That first grant was the foundation for what would eventually become the POLI-Drug Interaction Database. For the next twenty-nine years, I built that database entry by entry. It took ten years just to construct the primary architecture. It eventually grew to seventeen thousand distinct entries. Every single entry had to be rigorously verified through clinical trials, pharmacological modeling, and endless, exhausting peer review. I trained eleven graduate students over the course of that project.

From two thousand and nine until two thousand and nineteen, I was the sole Principal Investigator on NIH Grant R01AG052147. I wrote every single annual progress report. I designed every validation study. I authored four major published papers on the methodology. I filed two United States Patents—US10,847,223B2 and US11,003,112B2—entirely in my own name, paying a patent attorney out of my own pocket because I wanted absolute, unassailable control over my intellectual property.

In two thousand and twenty-two, Marcus came to me with a proposal. He had started NovaMed Analytics, and he wanted to license the POLI-DID for commercial distribution. He told me he could ‘develop’ it, bring it to the pharmaceutical market, and handle the corporate negotiations that I had always found deeply exhausting. I signed a distribution agreement. I reviewed the contract myself, ensuring that the IP remained entirely in my name. I thought that was sufficient. I thought my son understood the fundamental difference between a distributor and an author. He did not.

I had attended two prior pitch meetings with him over the last year. In the first meeting, I had watched him describe me to a room full of investors as ‘the academic lead on the theoretical framework.’ I had said nothing. I had told myself it was simply imprecise marketing language, not a deliberate misrepresentation. In the second meeting, he called me the ‘principal contributor.’ I had written the phrase down on my notepad. I had set my pen down. I had watched him carefully, waiting to see how far he would push the narrative.

I had been attending his meetings because he asked me to, and because a mother naturally wants to support what her son is building. But I had been watching him describe my twenty-nine years of grueling, solitary, groundbreaking scientific labor using smaller and smaller words. Framework. Contributor. Advisor.

At the Nexagen meeting, the slide in front of me clearly said ‘contributor’. The official federal grant record says ‘sole Principal Investigator’. Those are not the same words, and they do not carry the same legal weight. I had been letting him use the smaller words because I loved him. But the NIH program officer sitting across the table was not bound by maternal affection. He was bound by federal compliance law.

Dr. Yemi Adegoke placed his hands flat on the table, framing his laptop. The simple, deliberate motion immediately drew the attention of everyone in the room. Rachel Kim paused, her pen hovering over her notepad.

“I’m flagging a compliance concern,” Dr. Adegoke said, his voice quiet but carrying the immense, undeniable weight of federal authority.

The entire room went very, very still. In a pharmaceutical licensing meeting, a federal compliance flag from an NIH program officer is the equivalent of a bomb threat. It halts all negotiations, freezes all pending transactions, and immediately triggers an intense, microscopic review of the intellectual property chain.

“The NIH grant R01AG052147 lists a sole Principal Investigator,” Dr. Adegoke continued, looking directly at Marcus. “Your slide lists a contributor. These are different designations with entirely different IP ownership implications under federal grant law.”

Marcus blinked, his slick corporate persona fracturing for a fraction of a second before he hastily attempted to repair it. “Dr. Adegoke, our language simply reflects our internal partnership structure,” Marcus said, adopting a smooth, conciliatory tone. “NovaMed has co-licensing authority under our primary distribution agreement.”

I looked at my son. He was trying to blur the lines, trying to use corporate jargon to mask a fundamental misrepresentation of federal intellectual property.

“It does not reflect the grant record,” I said, my voice cutting sharply through the sterile air of the room. “Or the patents.”

Marcus turned to me, his eyes wide with a sudden, frantic panic. He had expected me to sit quietly in the back of the room, smiling benevolently while he sold my life’s work. “Mom,” Marcus hissed, his voice dropping into a desperate whisper. “This is not the time to—”

“I am the sole PI,” I said, ignoring him completely. “I hold both patents. This is exactly the time.”

Marcus’s attorney, a man in a very expensive suit who had been entirely silent up until this point, suddenly leaned forward. He recognized the catastrophic danger of the moment, and he attempted to throw a legal smoke grenade to obscure the reality of the situation.

“The distribution agreement signed in two thousand and twenty-two confers co-licensing authority to NovaMed,” the attorney said smoothly, addressing Dr. Adegoke. “Which establishes a joint IP ownership claim under the agreement’s development clause. The provenance is shared.”

Dr. Adegoke did not look up from his laptop. He simply typed another string of characters.

“NIH grant IP belongs to the PI’s institution and the PI’s named IP interest,” Dr. Adegoke said, quoting the federal statute from memory. “It does not belong to downstream distribution licensees. A distribution agreement cannot retroactively create joint IP ownership of federal grant data. The IP chain is clear. The gap you are describing does not exist in federal grant law.”

The attorney closed his mouth. He knew he was beaten. You cannot argue corporate contract law against federal grant compliance regulations in front of an NIH program officer.

I looked at Dr. Adegoke. He was the only person in the room who truly understood the architecture of my career. “I have the grant documentation on my laptop,” I said to Dr. Adegoke. I reached under my chair, feeling the heavy shape of my leather tote bag. “And I have something else.”

I pulled the heavy, rectangular package out of my leather tote bag. I peeled back the layers of protective bubble wrap, exposing the polished mahogany wood and the gleaming brass plate. I stood up and walked to the center of the white table. I placed the plaque down, facing Dr. Adegoke and Rachel Kim. It was the retirement plaque presented to me by my research team at the conclusion of my career at the NIH. It was not a corporate award. It was a deeply personal, fiercely earned monument to three decades of scientific rigor.

The brass plate caught the morning light perfectly. Dr. Adegoke leaned forward and read the inscription aloud.

“Dr. Priscilla Asante-Obeng,” he read. “Principal Investigator, POLI-Drug Interaction Database Project. Twenty-nine Years of Excellence, nineteen ninety-one to two thousand and twenty.”

He looked at the plaque, and then he looked at the slide projected on the wall. He turned his laptop around, displaying the official NIH RePORTER database entry on his screen.

“R01AG052147,” Dr. Adegoke read aloud, officially entering the information into the room’s verbal record. “Sole PI: Priscilla Asante-Obeng. Not contributor. Not co-developer. Sole.”

He closed his laptop. “The provenance slide is materially inaccurate.”

Rachel Kim placed her pen down on her legal pad. She looked at Marcus, her expression hardening into absolute, unforgiving corporate hostility.

“We need to pause these proceedings immediately,” Rachel Kim said, her voice like cracking ice. “We cannot license intellectual property with a disputed chain of title. The IP chain needs to be formally reestablished and completely verified before we execute any licensing instrument.”

Marcus was staring at the plaque on the table. He had borrowed that plaque from me two years ago. He had displayed it on a shelf in his office at NovaMed Analytics, using it as a prop to establish academic credibility during his video conferences. He had looked at it every single day for two years, and he had never once actually read the words inscribed on the brass plate. He had never once understood what ‘Principal Investigator’ actually meant.

“Mom,” Marcus said, his voice cracking, entirely stripped of its slick corporate polish. “I was going to credit you properly in the final agreement. I just needed the pitch to flow smoothly.”

I looked at my son, feeling a profound, exhausted sadness.

“The patents already credited me properly,” I said, my voice completely steady. “So did the federal grant. The problem was the slide.”

I reached out and picked up the mahogany plaque. The secondary arc was entirely resolved. The distribution agreement did not create joint ownership. My status as the sole Principal Investigator was confirmed by the highest federal authority in the room. The deal was frozen. I placed the plaque back into my leather bag. I did not look at Marcus again.

I drove home alone. The heavy leather bag sat on the passenger seat next to me, the mahogany plaque resting safely inside. I drove through the sprawling campus of the Research Triangle Park, past the massive glass buildings of the pharmaceutical conglomerates and the pristine lawns of the biotech startups. I had spent my entire adult life providing the foundational science that allowed these companies to exist. I had built the engine, and I had allowed my son to pretend he had designed the car.

Marcus called me that evening. I was sitting in my home office, drinking a cup of green tea. I watched my phone vibrate on the desk. I watched his name flash on the screen. I did not answer it.

Marcus told me later, in a long, frantic voicemail, that he had meant to give me proper attribution in the final licensing terms. He said he was just trying to secure the valuation, and that the corporate structure required NovaMed to present as the primary developer. I did not discuss it with him. Intentions are not grant records. Intentions are not patents. I had signed a distribution agreement to let him sell the product of my labor. I had not signed over my name, my history, or my fundamental identity as a scientist.

I stood up from my desk and walked over to the blank space on my office wall. I took the mahogany plaque out of the leather bag. I hung it on the wall, adjusting it until it was perfectly straight. I stood in the doorway and looked at it. Twenty-nine years of grueling, relentless excellence, forged in basement offices and sterile laboratories, summarized in a single brass inscription.

Marcus had asked me to be his scientific advisor. He wanted me to be a quiet, supportive accessory to his own ambition. But I am not anyone’s advisor in my own work.

I am the investigator.

I had spent two years attending his pitch meetings, sitting quietly in the back of the room, and letting him choose my title. I chose it back today.

THE END!